131 related articles for article (PubMed ID: 38750780)
21. Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis.
Xiong J; He T; Wang M; Nie L; Zhang Y; Wang Y; Huang Y; Feng B; Zhang J; Zhao J
J Nephrol; 2019 Oct; 32(5):791-802. PubMed ID: 30888644
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of plasma galectin-3 levels in acute coronary syndrome.
Obeid S; Yousif N; Davies A; Loretz R; Saleh L; Niederseer D; Noor HA; Amin H; Mach F; Gencer B; Räber L; Windecker S; Templin C; Nanchen D; Rodondi N; Muller O; Matter CM; von Eckardstein A; Lüscher TF
Eur Heart J Acute Cardiovasc Care; 2020 Dec; 9(8):869-878. PubMed ID: 33300826
[TBL] [Abstract][Full Text] [Related]
23. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis.
Chen H; Chen C; Fang J; Wang R; Nie W
Heart Fail Rev; 2020 Mar; 25(2):331-341. PubMed ID: 31641977
[TBL] [Abstract][Full Text] [Related]
24. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
25. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites.
McEvoy JW; Chen Y; Halushka MK; Christenson E; Ballantyne CM; Blumenthal RS; Christenson RH; Selvin E
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27178204
[TBL] [Abstract][Full Text] [Related]
27. Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD.
Steubl D; Schneider MP; Meiselbach H; Nadal J; Schmid MC; Saritas T; Krane V; Sommerer C; Baid-Agrawal S; Voelkl J; Kotsis F; Köttgen A; Eckardt KU; Scherberich JE;
Clin J Am Soc Nephrol; 2020 May; 15(5):616-624. PubMed ID: 32291270
[TBL] [Abstract][Full Text] [Related]
28. Galectins for Diagnosis and Prognostic Assessment of Human Diseases: An Overview of Meta-Analyses.
Liu Y; Meng H; Xu S; Qi X
Med Sci Monit; 2020 Aug; 26():e923901. PubMed ID: 32744262
[TBL] [Abstract][Full Text] [Related]
29. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.
Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
Am Heart J; 2014 May; 167(5):674-82.e1. PubMed ID: 24766977
[TBL] [Abstract][Full Text] [Related]
30. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus.
Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
Diabetologia; 2018 May; 61(5):1212-1219. PubMed ID: 29417184
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of Galectin-3 in Exacerbations of Chronic Obstructive Pulmonary Disease.
Berber NK; Atlı S; Geçkil AA; Erdem M; Kıran TR; Otlu Ö; İn E
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674175
[No Abstract] [Full Text] [Related]
32. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Deo R; Yang W; Khan AM; Bansal N; Zhang X; Leonard MB; Keane MG; Soliman EZ; Steigerwalt S; Townsend RR; Shlipak MG; Feldman HI;
Hypertension; 2014 Jul; 64(1):103-10. PubMed ID: 24752431
[TBL] [Abstract][Full Text] [Related]
33. Association of serum chloride level with mortality and cardiovascular events in chronic kidney disease: the CKD-ROUTE study.
Mandai S; Kanda E; Iimori S; Naito S; Noda Y; Kikuchi H; Akazawa M; Oi K; Toda T; Sohara E; Okado T; Sasaki S; Rai T; Uchida S
Clin Exp Nephrol; 2017 Feb; 21(1):104-111. PubMed ID: 27039905
[TBL] [Abstract][Full Text] [Related]
34. Elevated galectin-3 precedes the development of CKD.
O'Seaghdha CM; Hwang SJ; Ho JE; Vasan RS; Levy D; Fox CS
J Am Soc Nephrol; 2013 Sep; 24(9):1470-7. PubMed ID: 23766533
[TBL] [Abstract][Full Text] [Related]
35. Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?
Ozkan G; Ulusoy S; Menteşe A; Guvercin B; Karahan SC; Yavuz A; Altay DU; Ocal M
Clin Biochem; 2015 Aug; 48(12):768-73. PubMed ID: 25977067
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis.
Wu C; Lv Z; Li X; Zhou X; Mao W; Zhu M
Heart Surg Forum; 2021 Mar; 24(2):E327-E332. PubMed ID: 33798049
[TBL] [Abstract][Full Text] [Related]
37. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
38. Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality.
Ursli M; Zierfuss B; Grigassy T; Pesau G; Koppensteiner R; Schernthaner GH; Höbaus C
Atherosclerosis; 2022 Jan; 341():7-12. PubMed ID: 34929561
[TBL] [Abstract][Full Text] [Related]
39. Antioxidants for chronic kidney disease.
Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.
Ghorbani A; Bhambhani V; Christenson RH; Meijers WC; de Boer RA; Levy D; Larson MG; Ho JE
J Am Coll Cardiol; 2018 Dec; 72(25):3246-3254. PubMed ID: 30573026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
